IDH2 and cholangiocarcinoma: More recently, the phase III ClarIDHy trial randomized 185 previously treated, IDH-mutant CCA patients to ivosidenib or matched placebo, with patients receiving placebo that were allowed to crossover to ivosidenib following radiographic progression [69].